Evaluation of Tumor Markers (CEA, CA 15-3, CA 125) in Endometrial Cancer Differentiation and Abnormal Uterine Bleeding

Sasanpour, Pegah; Ghasemi, Marzieh; Nazemian, Maryam; Noori, Narjes; Ansari, Hossein

doi:10.30699/jogcr.9.2.150

Document Type : Original Research Article

Authors

¹ Department of Radiotherapy, Zaheden University of Medical Sciences, Zahedan, Iran

² Department of Obstetrics and Gynecology, Zahedan University of Medical Sciences, Zahedan, Iran

³ Pregnancy Health Research Center, Zahedan University of Medical Sciences, Zahedan, Iran

⁴ Department of Epidemiology and Biostatistics, School of Health, Zaheden University of Medical Sciences, Zahedan, Iran

https://doi.org/10.30699/jogcr.9.2.150

Abstract

Background & Objective: Endometrial cancer is the most prevalent type of genital system cancers. It is needed to assess discrimination power of CEA, CA 15-3, CA 125 tumor markers in endometrial cancer patients and moreover in cases with abnormal uterine bleeding. We examined tumor markers (CA 15-3, CA 125, CEA) in differentiating endometrial cancer and unusual uterine bleeding.
Materials & Methods: The present case-control study was conducted on 60 women with endometrial cancer and evidence of abnormal uterine bleeding who referred to Ali Ibn Abitaleb Hospital in Zahedan in 2021. The sampling method was easy and accessible and was used to collect observation information, examination, and data form data. For data analysis, SPSS software version 26, statistical graphs and independent t-test were used.
Results: The difference in serum levels of CEA marker tumor in patients of case (endometrial cancer patients) and control (abnormal uterine bleeding patients) was statistically significant. Differences in serum levels of CA 15-3 tumor marker in patients between case group (endometrial cancer patients) and control (patients with abnormal uterine bleeding) and difference in serum levels of CA 125 tumor marker in patients between case (endometrial cancer patients) and control groups (bleeding patients) uterine abnormalities were not statistically significant.
Conclusion: Serum level of CEA tumor marker has a statistically significant relationship with endometrial cancer patients and abnormal bleeding patients, but serum tumor marker level CA 15-3 and serum tumor marker CA 125 and with endometrial cancer patients and abnormal bleeding patients do not have.

Keywords

Main Subjects

Gynecology Oncology

References

1. Rasool N, Fader AN, Seamon L, Neubauer NL, Shahin FA, Alexander HA, et al. Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: An analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol. 2010;116(1):10-4. [DOI:10.1016/j.ygyno.2009.10.043] [PMID]

2. Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA. 2018;178(9):1210-22. [DOI:10.1001/jamainternmed.2018.2820] [PMID] [PMCID]

3. Pennant ME, Mehta R, Moody P, Hackett G, Prentice A, Sharp SJ, Lakshman R. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG: Int J Obstet Gynaecol. 2017;124(3):404-11. [DOI:10.1111/1471-0528.14385] [PMID] [PMCID]

4. Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: A systematic review. Maturitas. 2016;91:25-35. [DOI:10.1016/j.maturitas.2016.05.013] [PMID]

5. Lei J, Yan S, Guo X, Wang F, Zhang G, Guo R. Identification of Distinct Molecular Subtypes of Endometrioid Adenocarcinoma. Front Biol. 2021;12:568779. [DOI:10.3389/fgene.2021.568779] [PMID] [PMCID]

6. Kim B, Park Y, Kim B, Ahn HJ, Lee K-A, Chung JE, Han SW. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. J Clin Lab Anal. 2019;33(1):e22624. [DOI:10.1002/jcla.22624] [PMID] [PMCID]

7. Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, et al. Risk factors for endometrial cancer: An umbrella review of the literature. Int J Cancer. 2019;145(7):1719-30. [DOI:10.1002/ijc.31961] [PMID]

8. Machado F, Rodríguez JR, León JPH, Rodríguez JR, Parrilla JJ, Abad L. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. Eur J Gynaecol Oncol. 2005;26(3):257-65.

9. Rowe IJ, Baber RJ. The effects of phytoestrogens on postmenopausal health. Climacteric. 2021;24(1):57-63. [DOI:10.1080/13697137.2020.1863356] [PMID]

10. Nees LK, Heublein S, Steinmacher S, Juhasz-Böss I, Brucker S, Tempfer CB, Wallwiener M. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet. 2022;06(2):407-21. [DOI:10.1007/s00404-021-06380-5] [PMID] [PMCID]

11. Giannella L, Cerami LB, Setti T, Bergamini E, Boselli F. Prediction of Endometrial Hyperplasia and Cancer among Premenopausal Women with Abnormal Uterine Bleeding. Biomed Res Int. 2019;2019:8598152. [DOI:10.1155/2019/8598152] [PMID] [PMCID]

12. Moradi M, Niazi A, Parker M, Sneddon A, Lopez V, Ellwood D. Endometriosis-associated Symptoms and Diagnostic Delay: An Online Survey. J Obstet Gynecol Cancer Res. 2022;7(6):479-88. [DOI:10.30699/jogcr.7.6.479]

13. Hanson B, Johnstone E, Dorais J, Silver B, Peterson CM, Hotaling J. Female infertility, infertility-associated diagnoses, and comorbidities: a review. J Assist Reprod Genet. 2017;34(2):167-77. [DOI:10.1007/s10815-016-0836-8] [PMID] [PMCID]

14. Matanes E, Volodarsky-Perel A, Eisenberg N, Rottenstreich M, Yasmeen A, Mitric C, et al. Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2021;28(5):947-56. [DOI:10.1016/j.jmig.2020.11.023] [PMID]

15. Doluoglu SG, Karaca M, Erol O. Correlation of Preoperative Serum and Intraoperative Peritoneal Lavage Fluid Ca-125 Levels with Postoperative Tumor Histology in Patients with Endometrial Cancer: A Prospective-Controlled Study. J Invest Surg. 2022;35(6):1248-52. [DOI:10.1080/08941939.2021.2024307] [PMID]

16. Zhou X, Wang H, Wang X. Preoperative CA125 and fibrinogen in patients with endometrial cancer: a risk model for predicting lymphovascular space invasion. J Gynecol Oncol. 2017;28(2):e11. [DOI:10.3802/jgo.2017.28.e11] [PMID] [PMCID]

17. Kozakiewicz B, Chądzyńska M, Dmoch-Gajzlerska E, Stefaniak M. Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI. Tumour Biol. 2016;37(7):9367-74. [DOI:10.1007/s13277-016-4784-9] [PMID] [PMCID]

18. Kumar NU, Sridhar MG, Srilatha K, Habebullah S. CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding. Afr Health Sci. 2018;18(4):972-8. [DOI:10.4314/ahs.v18i4.17] [PMID] [PMCID]

19. Fini E, Nasirian N, Hosein Beigy B. Evaluating Specivity, Sensitivity, Positive and Negative Predictive Values of CA125 for Diagnosing Ovarian Cancer. J Arak Univ Med Sci. 2021;24(2):196-203. [DOI:10.32598/jams.24.2.6002.1]

20. Kanat-Pektas M, Yenicesu O, Gungor T, Bilge U. Predictive power of sexual hormones and tumor markers in endometrial cancer. Arch Obstet Gynaecol. 2010;281:709-15. [DOI:10.1007/s00404-009-1228-4] [PMID]

Journal of Obstetrics, Gynecology and Cancer Research

Evaluation of Tumor Markers (CEA, CA 15-3, CA 125) in Endometrial Cancer Differentiation and Abnormal Uterine Bleeding

References

References

Volume 9, Issue 2 - Serial Number 37
March and April 2024
Pages 150-153

Evaluation of Tumor Markers (CEA, CA 15-3, CA 125) in Endometrial Cancer Differentiation and Abnormal Uterine Bleeding

References

References

Volume 9, Issue 2 - Serial Number 37March and April 2024Pages 150-153

Volume 9, Issue 2 - Serial Number 37
March and April 2024
Pages 150-153